A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

NCT04881760 · Completed

Last updated 2026-05-28

This clinical trial tests the investigational drug LY3437943 in adults who have obesity or are overweight to evaluate its effects on body weight.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 338 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-05 · est. completion 2022-11

Where 28 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT04881760 ↗

Description as written by the study sponsor.

This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.

Treatments tested

LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Mean Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04881760 ↗